Aarti Pharmalabs Limited Achieves Key Sustainability Milestone with Approval of GHG Emission Reduction Targets by Science Based Target initiative (SBTi).
Aarti Pharmalabs Becomes 6th Indian Pharma/CDMO to Earn SBTi Approval for all 3 Scopes Since 2022 Demerger.
Mumbai, India – April 15, 2025: Aarti Pharmalabs Limited is proud to announce that its ambitious Science Based Targets (SBTs) for emissions have been officially approved by the Science Based Targets initiative (SBTi). This significant achievement underscores the company's deep commitment to environmental sustainability and proactive climate action, aligning its emission reduction goals with the objectives of the Paris Agreement. This approval encompasses all three emission scopes - Scope 1, Scope 2, and Scope 3 making Aarti Pharmalabs Limited the 6th pharmaceutical company in India to achieve this comprehensive validation, a feat accomplished just three years after its 2022 demerger.
The approval by SBTi, a globally recognized body that defines and promotes best practices in science-based target setting, validates Aarti Pharmalabs Limited’s dedication to contributing to a low-carbon economy. This milestone reflects the culmination of months of rigorous effort involving comprehensive carbon footprint assessment, the implementation of energy-efficient initiatives across its operations, and active engagement with its value chain partners.
"We are excited to embark on this next phase of our sustainability journey and are confident that by working together, we can make a meaningful difference," said Mrs. Hetal Gogri Gala, Vice Chairperson and Managing Director at Aarti Pharmalabs Limited.
"This approval is a testament to our unwavering commitment to building a sustainable future and reflects the collective dedication of our entire team. We recognize the urgent need for climate action, and these targets provide a clear roadmap for reducing our environmental impact in line with global climate goals," said Mr. Narendra J. Salvi, Managing Director at Aarti Pharmalabs Limited.
"This is more than just a milestone; it is a reaffirmation of our purpose to operate responsibly and contribute to a greener, more resilient future," added Mr. Tanaji S. Shinde, Head of Sustainability at Aarti Pharmalabs Limited.
Aarti Pharmalabs has committed to reducing Scope 1 and 2 emissions and engaging suppliers to align with Scope 3 targets, as mentioned below,
“Overall Net-Zero Target: Aarti Pharmalabs Limited commits to reach net-zero greenhouse gas emissions across the value chain by FY2050.
Near-Term Targets: Aarti Pharmalabs Limited commits to reduce absolute scope 1 and 2 GHG emissions 37.8% by FY2030 from a FY2024 base year. Aarti Pharmalabs Limited also commits to reduce absolute scope 3 GHG emissions 22.5% within the same timeframe.
Long-Term Targets: Aarti Pharmalabs Limited commits to reduce absolute scope 1 and 2 GHG emissions 90% by FY2050 from a FY2024 base year. Aarti Pharmalabs Limited also commits to reduce absolute scope 3 GHG emissions 90% within the same timeframe.
The target boundary includes land-related emissions and removals from bioenergy feedstocks.”
Ensuring a holistic approach to decarbonization. Moving forward, the company will focus on driving innovation through the adoption of low-carbon technologies, further optimizing its operational efficiency, and fostering strong collaborations with its partners throughout the value chain to achieve these ambitious targets.
Beyond the company's inherent environmental responsibility, the approval of its SBTi’s is also expected to strengthen Aarti Pharmalabs' market position. This achievement will enhance its attractiveness to sustainability-conscious business partners, ensure preparedness for evolving environmental regulations, and ultimately contribute to the creation of long-term value for stakeholders.
About Aarti Pharmalabs Limited:
Aarti Pharmalabs Limited (NSE: AARTIPHARM | BSE: 543748) is a prominent Indian pharmaceutical and nutraceutical manufacturer with a global presence. Since its demerger in 2022, Aarti Pharmalabs Limited has accelerated its focus on innovation, sustainability, and global leadership in the pharmaceutical and nutraceutical sectors. The company specializes in producing generic APIs, intermediates, and xanthine derivatives (including Synthetic Caffeine). Additionally, Aarti Pharmalabs Limited offers comprehensive CDMO services for small molecule drug substances, catering to clinical and commercial phase projects for innovator pharma companies, with dedicated facilities for HPAPIs, corticosteroids, cytotoxic, and oncology products.
About the Science Based Targets initiative (SBTi):
The Science Based Targets initiative (SBTi) is a collaboration between CDP, the United Nations Global Compact, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF). The SBTi defines and promotes best practices in science-based target setting, offers resources and guidance to reduce barriers to adoption, and independently assesses and approves companies’ targets.
Contact:
Name of Contact: Mr. Anuj Sonpal
Email: aarti@valoremadvisors.com
Contact Number: +91-22-4903 9500
Website: www.aartipharmalabs.com
